Claims for Patent: 6,649,375

Summary for Patent: 6,649,375

Title:	Adenoviral vectors for enhanced gene expression
Abstract:	An adenoviral vector including at least one DNA sequence encoding a clotting factor, such as, for example, Factor VIII, or Factor IX. Such vectors may be administered to a host in an amount effective to treat hemophilia in the host. The vectors infect hepatocytes very efficiently, whereby the hepatocytes express the DNA sequence encoding the clotting factor.
Inventor(s):	Connelly; Sheila (Gaithersburg, MD), Kaleko; Michael (Rockville, MD), Smith; Theodore (Germantown, MD)
Assignee:	Genetic Theraphy, Inc. (Gaithersburg, MD)
Application Number:	09/150,811
Patent Claims:	1. An adenoviral vector comprising at least one heterologous DNA sequence and at least one intron which is not part of the adenoviral genome, wherein said vector is free of adenoviral DNA sequences encoding E1 proteins. 2. The vector of claim 1, further comprising a 3' untranslated region, a 5' untranslated region, or both a 5' untranslated region and a 3' untranslated region operatively linked to said heterologous DNA sequence. 3. The vector of claim 1, wherein said heterologous DNA sequence encodes a heterologous protein. 4. The vector of claim 1, wherein said heterologous DNA sequence is selected from the group consisting of: DNA encoding Factor VIII; DNA encoding Factor IX; DNA encoding a cytokine; DNA encoding a tumor necrosis factor (TNF); DNA encoding an interferon; DNA encoding an interleukin; DNA encoding GM-CSF; DNA encoding adenosine deaminase, or ADA; DNA encoding a cellular growth factor; DNA encoding soluble CD4; DNA encoding an LDL receptor; DNA encoding ApoE; DNA encoding ApoC; DNA encoding ApoA1; DNA encoding alpha-1 antitrypsin (.alpha.1AT); DNA encoding ornithine transcarbamylase (OTC); DNA encoding CFTR; DNA encoding insulin; DNA encoding a viral thymidine kinase; and DNA encoding an antisense sequence which inihibits viral replication. 5. The vector of claim 1, wherein said intron is at least a portion of an intron of the Factor IX gene. 6. The vector of vector claim 1, wherein said intron is at least a portion of an intron of the Factor VIII gene. 7. The vector of claim 1, wherein said intron comprises the first intron of the apolipoprotein A-1 gene. 8. The vector of claim 3, wherein said heterologous DNA sequence and said intron are from the same gene. 9. The vector of claim 3, wherein said heterologous DNA sequence and said intron are from different genes. 10. The vector of claim 5, wherein said intron is the full seventh intron of the Factor IX gene. 11. An adenoviral vector comprising at least one heterologous DNA sequence and at least one intron which is not part of the adenoviral genome, wherein said vector is free of at least the majority of adenoviral E1 and E3 DNA sequences. 12. The vector of claim 11, wherein said vector also is free of at least a portion of adenoviral E2 DNA sequences. 13. The vector of claim 11, wherein said vector also is free of at least a portion of adenoviral E4 DNA sequences. 14. The vector of claim 11, wherein said vector also is free of at least a portion of adenoviral E2 and E4 DNA sequences. 15. The vector of claim 11, further comprising a 3' untranslated region, a 5' untranslated region, or both a 5' untranslated region and a 3' untranslated region operatively linked to said heterologous DNA sequence. 16. The vector of claim 11, wherein said heterologous DNA sequence encodes a heterologous protein. 17. The vector of claim 11, wherein said heterologous DNA sequence is selected from the group consisting of: DNA encoding Factor VIII; DNA encoding Factor IX; DNA encoding a cytokine; DNA encoding a tumor necrosis factor (TNF); DNA encoding an interferon; DNA encoding an interleukin; DNA encoding GM-CSF; DNA encoding adenosine deaminase, or ADA; DNA encoding a cellular growth factor; DNA encoding soluble CD4; DNA encoding an LDL receptor; DNA encoding ApoE; DNA encoding ApoC; DNA encoding ApoA1; DNA encoding alpha-1 antitrypsin (.alpha.1AT); DNA encoding ornithine transcarbamylase (OTC); DNA encoding CFTR; DNA encoding insulin; DNA encoding a viral thymidine kinase; and DNA encoding an antisense sequence which inihibits viral replication. 18. The vector of claim 11, wherein said intron is at least a portion of an intron of the Factor IX gene. 19. The vector of claim 11, wherein said intron is at least a portion of an intron of the Factor VIII gene. 20. The vector of claim 11, wherein said intron comprises the first intron of the apolipoprotein A-1 gene. 21. The vector of claim 16, wherein said heterologous DNA sequence and said intron are from the same gene. 22. The vector of claim 16, wherein said heterologous DNA sequence and said intron are from different genes. 23. The vector of claim 18, wherein said intron is the full seventh intron of the Factor IX gene. 24. An adenoviral vector comprising at least one heterologous DNA sequence and at least one intron selected from the group consisting of at least a portion of an intron of the Factor IX gene, the full seventh intron of the Factor IX gene, at least a portion of an intron of the Factor VIII gene and the first intron of the apolipoprotein A-1 gene, said at least one intron enhancing expression of said at least one heterologous DNA sequence. 25. The vector of claim 24, wherein said vector is free of adenoviral DNA sequences encoding E1 proteins. 26. The vector of claim 24, wherein said vector is free of at least the majority of adenoviral E1 and E3 DNA sequences. 27. The vector of claim 24, further comprising a 3' untranslated region, a 5' untranslated region, or both a 5' untranslated region and a 3' untranslated region operatively linked to said heterologous DNA sequence. 28. The vector of claim 24, wherein said heterologous DNA sequence encodes a heterologous protein. 29. The vector of claim 24, wherein said heterologous DNA sequence is selected from the group consisting of: DNA encoding Factor VIII; DNA encoding Factor IX; DNA encoding a cytokine; DNA encoding a tumor necrosis factor (TNF); DNA encoding an interferon; DNA encoding an interleukin; DNA encoding GM-CSF; DNA encoding adenosine deaminase, or ADA; DNA encoding a cellular growth factor; DNA encoding soluble CD4; DNA encoding an LDL receptor; DNA encoding ApoE; DNA encoding ApoC; DNA encoding ApoA1; DNA encoding alpha-1 antitrypsin (.alpha.1AT); DNA encoding ornithine transcarbamylase (OTC); DNA encoding CFTR; DNA encoding insulin; DNA encoding a viral thymidine kinase; and DNA encoding an antisense sequence which inihibits viral replication. 30. The vector of claim 24, wherein said intron is at least a portion of an intron of the Factor IX gene. 31. The vector of claim 24, wherein said intron is at least a portion of an intron of the Factor VIII gene. 32. The vector of claim 24, wherein said intron comprises the first intron of the apolipoprotein A-1 gene. 33. The vector of claim 26, wherein said vector also is free of at least a portion of adenoviral E2 DNA sequences. 34. The vector of claim 26, wherein said vector also is free of at least a portion of adenoviral E4 DNA sequences. 35. The vector of claim 26, wherein said vector also is free of at least a portion of adenoviral E2 and E4 DNA sequences. 36. The vector of claim 28, wherein said heterologous DNA sequence and said intron are from the same gene. 37. The vector of claim 28, wherein said heterologous DNA sequence and said intron are from different genes. 38. The vector of claim 30, wherein said intron is the full seventh intron of the Factor IX gene. 39. A method of expressing a heterologous DNA sequence contained in an adenoviral vector, comprising operatively linking said heterologous DNA sequence with at least one intron selected from the group consisting of at least a portion of an intron of the Factor IX gene, the full seventh intron of the Factor IX gene, at least a portion of an intron of the factor VIII gene and the first intron of the apolipoprotein A-1 gene, said at least one intron enhancing expression of said heterologous DNA sequence. 40. The method of claim 39, wherein said vector is free of adenoviral DNA sequences encoding E1 proteins. 41. The method of claim 39, wherein said vector is free of at least the majority of adenoviral E1 and E3 DNA sequences. 42. The method of claim 39, further comprising operatively linking said heterologous DNA sequence with a 3' untranslated region, a 5' untranslated region, or both a 5' untranslated region and a 3' untranslated region. 43. The method of claim 39, wherein said heterologous DNA sequence encodes a heterologous protein. 44. The method of claim 39, wherein said heterologous DNA sequence is selected from the group consisting of: DNA encoding Factor VIII; DNA encoding Factor IX; DNA encoding a cytokine; DNA encoding a tumor necrosis factor (TNF); DNA encoding an interferon; DNA encoding an interleukin; DNA encoding GM-CSF; DNA encoding adenosine deaminase, or ADA; DNA encoding a cellular growth factor; DNA encoding soluble CD4; DNA encoding an LDL receptor; DNA encoding ApoE; DNA encoding ApoC; DNA encoding ApoA1; DNA encoding alpha-1 antitrypsin (.alpha.1AT); DNA encoding ornithine transcarbamylase (OTC); DNA encoding CFTR; DNA encoding insulin; DNA encoding a viral thymidine kinase; and DNA encoding an antisense sequence which inihibits viral replication. 45. The method of claim 39, wherein said intron is at least a portion of an intron of the Factor IX gene. 46. The method of claim 39, wherein said intron is at least a portion of an intron of the Factor VIII gene. 47. The method of claim 39, wherein said intron comprises the first intron of the apolipoprotein A-1 gene. 48. The method of claim 41, wherein said vector also is free of at least a portion of adenoviral E2 DNA sequences. 49. The method of claim 41, wherein said vector also is free of at least a portion of adenoviral E4 DNA sequences. 50. The method of claim 41, wherein said vector also is free of at least a portion of adenoviral E2 and E4 DNA sequences. 51. The method of claim 43, wherein said heterologous DNA sequence and said intron are from the same gene. 52. The method of claim 43, wherein said heterologous DNA sequence and said intron are from different genes. 53. The method of claim 45, wherein said intron is the full seventh intron of the Factor IX gene. 54. An adenoviral vector comprising at least one heterologous DNA sequence, wherein said vector is free of adenoviral DNA sequences encoding E1 proteins and said at least one heterologous DNA sequence comprises at least one intron. 55. The vector of claim 54, further comprising a 3' untranslated region, a 5' untranslated region, or both a 5' untranslated region and a 3' untranslated region operatively linked to said heterologous DNA sequence. 56. The vector of claim 54, wherein said heterologous DNA sequence encodes a heterologous protein. 57. The vector of claim 54, wherein said heterologous DNA sequence is selected from the group consisting of: DNA encoding Factor VIII; DNA encoding Factor IX; DNA encoding a cytokine; DNA encoding a tumor necrosis factor (TNF); DNA encoding an interferon; DNA encoding an interleukin; DNA encoding GM-CSF; DNA encoding adenosine deaminase, or ADA; DNA encoding a cellular growth factor; DNA encoding soluble CD4; DNA encoding an LDL receptor; DNA encoding ApoE; DNA encoding ApoC; DNA encoding ApoA1; DNA encoding alpha-1 antitrypsin (.alpha.1AT); DNA encoding ornithine transcarbamylase (OTC); DNA encoding CFTR; DNA encoding insulin; DNA encoding a viral thymidine kinase; and DNA encoding an antisense sequence which inihibits viral replication. 58. The vector of claim 54, wherein said intron is at least a portion of an intron of the Factor IX gene. 59. The vector of claim 54, wherein said intron is at least a portion of an intron of the Factor VIII gene. 60. The vector of claim 54, wherein said intron comprises the first intron of the apolipoprotein A-1 gene. 61. The vector of claim 56, wherein said heterologous DNA sequence and said intron are from the same gene. 62. The vector of claim 56, wherein said heterologous DNA sequence and said intron are from different genes. 63. The vector of claim 58, wherein said intron is the full seventh intron of the Factor IX gene. 64. An adenoviral vector comprising at least one heterologous DNA sequence wherein said vector is free of at least the majority of adenoviral E1 and E3 DNA sequences and said at least one heterologous DNA sequence comprises at least one intron. 65. The vector of claim 64, wherein said vector also is free of at least a portion of adenoviral E2 DNA sequences. 66. The vector of claim 64, wherein said vector also is free of at least a portion of adenoviral E4 DNA sequences. 67. The vector of claim 64, wherein said vector also is free of at least a portion of adenoviral E2 and E4 DNA sequences. 68. The vector of claim 64, further comprising a 3' untranslated region, a 5' untranslated region, or both a 5' untranslated region and a 3' untranslated region operatively linked to said heterologous DNA sequence. 69. The vector of claim 64, wherein said heterologous DNA sequence encodes a heterologous protein. 70. The vector of claim 64, wherein said heterologous DNA sequence is selected from the group consisting of: DNA encoding Factor VIII; DNA encoding Factor IX; DNA encoding a cytokine; DNA encoding a tumor necrosis factor (TNF); DNA encoding an interferon; DNA encoding an interleukin; DNA encoding GM-CSF; DNA encoding adenosine deaminase, or ADA; DNA encoding a cellular growth factor; DNA encoding soluble CD4; DNA encoding an LDL receptor; DNA encoding ApoE; DNA encoding ApoC; DNA encoding ApoA1; DNA encoding alpha-1 antitrypsin (.alpha.1AT); DNA encoding ornithine transcarbamylase (OTC); DNA encoding CFTR; DNA encoding insulin; DNA encoding a viral thymidine kinase; and DNA encoding an antisense sequence which inihibits viral replication. 71. The vector of claim 64, wherein said intron is at least a portion of an intron of the Factor IX gene. 72. The vector of claim 64, wherein said intron is at least a portion of an intron of the Factor VIII gene. 73. The vector of claim 64, wherein said intron comprises the first intron of the apolipoprotein A-1 gene. 74. The vector of claim 69, wherein said heterologous DNA sequence and said intron are from the same gene. 75. The vector of claim 69, wherein said heterologous DNA sequence and said intron are from different genes. 76. The vector of claim 71, wherein said intron is the full seventh intron of the Factor IX gene. 77. An adenoviral vector comprising at least one heterologous DNA sequence, said at least one heterologous DNA sequence comprising at least one intron selected from the group consisting of at least a portion of an intron of the Factor IX gene, the full seventh intron of the Factor IX gene, at least a portion of an intron of the Factor VIII gene and the first intron of the apolipoprotein A-1 gene, wherein said at least one intron enhances expression of said at least one heterologous DNA sequence. 78. The vector of claim 77, wherein said vector is free of adenoviral DNA sequences encoding E1 proteins. 79. The vector of claim 77, wherein said vector is free of at least the majority of adenoviral E1 and E3 DNA sequences. 80. The vector of claim 77, further comprising a 3' untranslated region, a 5' untranslated region, or both a 5' untranslated region and a 3' untranslated region operatively linked to said heterologous DNA sequence. 81. The vector of claim 77, wherein said heterologous DNA sequence encodes a heterologous protein. 82. The vector of claim 77, wherein said heterologous DNA sequence is selected from the group consisting of: DNA encoding Factor VIII; DNA encoding Factor IX; DNA encoding a cytokine; DNA encoding a tumor necrosis factor (TNF); DNA encoding an interferon; DNA encoding an interleukin; DNA encoding GM-CSF; DNA encoding adenosine deaminase, or ADA; DNA encoding a cellular growth factor; DNA encoding soluble CD4; DNA encoding an LDL receptor; DNA encoding ApoE; DNA encoding ApoC; DNA encoding ApoA1; DNA encoding alpha-1 antitrypsin (.alpha.1AT); DNA encoding ornithine transcarbamylase (OTC); DNA encoding CFTR; DNA encoding insulin; DNA encoding a viral thymidine kinase; and DNA encoding an antisense sequence which inihibits viral replication. 83. The vector of claim 77, wherein said intron is at least a portion of an intron of the Factor IX gene. 84. The vector of claim 77, wherein said intron is at least a portion of an intron of the Factor VIII gene. 85. The vector of claim 77, wherein said intron comprises the first intron of the apolipoprotein A-1 gene. 86. The vector of claim 79, wherein said vector also is free of at least a portion of adenoviral E2 DNA sequences. 87. The vector of claim 79, wherein said vector also is free of at least a portion of adenoviral E4 DNA sequences. 88. The vector of claim 79, wherein said vector also is free of at least a portion of adenoviral E2 and E4 DNA sequences. 89. The vector of claim 81, wherein said heterologous DNA sequence and said intron are from the same gene. 90. The vector of claim 81, wherein said heterologous DNA sequence and said intron are from different genes. 91. The vector of claim 83, wherein said intron is the full seventh intron of the Factor IX gene. 92. A method of expressing a heterologous DNA sequence contained in an adenoviral vector, comprising operatively linking said heterologous DNA sequence with at least one intron selected from the group consisting of at least a portion of an intron of the Factor IX gene, the full seventh intron of the Factor IX gene, at least a portion of an intron of the Factor VIII gene and the first intron of the apolipoprotein A-1 gene, wherein said at least one intron enhances expression of said heterologous DNA sequence. 93. The method of claim 92, wherein said vector is free of adenoviral DNA sequences encoding E1 proteins. 94. The method of claim 92, wherein said vector is free of at least the majority of adenoviral E1 and E3 DNA sequences. 95. The method of claim 92, further comprising operatively linking said heterologous DNA sequence with a 3' untranslated region, a 5' untranslated region, or both a 5' untranslated region and a 3' untranslated region. 96. The method of claim 92, wherein said heterologous DNA sequence encodes a heterologous protein. 97. The method of claim 92, wherein said heterologous DNA sequence is selected from the group consisting of: DNA encoding Factor VIII; DNA encoding Factor IX; DNA encoding a cytokine; DNA encoding a tumor necrosis factor (TNF); DNA encoding an interferon; DNA encoding an interleukin; DNA encoding GM-CSF; DNA encoding adenosine deaminase, or ADA; DNA encoding a cellular growth factor; DNA encoding soluble CD4; DNA encoding an LDL receptor; DNA encoding ApoE; DNA encoding ApoC; DNA encoding ApoA1; DNA encoding alpha-1 antitrypsin (.alpha.1AT); DNA encoding ornithine transcarbamylase (OTC); DNA encoding CFTR; DNA encoding insulin; DNA encoding a viral thymidine kinase; and DNA encoding an antisense sequence which inihibits viral replication. 98. The method of claim 92, wherein said intron is at least a portion of an intron of the Factor IX gene. 99. The method of claim 94, wherein said vector also is free of at least a portion of adenoviral E2 DNA sequences. 100. The method of claim 94, wherein said vector also is free of at least a portion of adenoviral E4 DNA sequences. 101. The method of claim 94, wherein said vector also is free of at least a portion of adenoviral E2 and E4 DNA sequences. 102. The method of claim 96, wherein said heterologous DNA sequence and said intron are from the same gene. 103. The method of claim 96, wherein said heterologous DNA sequence and said intron are from different genes. 104. The method of claim 98, wherein said intron is the full seventh intron of the Factor IX gene. 105. The method of claim 92, wherein said intron is at least a portion of an intron of the Factor VIII gene. 106. The method of claim 92, wherein said intron comprises the first intron of the apolipoprotein A-1 gene.

Details for Patent 6,649,375

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2013-06-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2013-06-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2013-06-10